From the databaseWhat the row says.
Every entry follows the same shape: what is happening, the mechanism, and the recommendation.
Pair type
Conflict, Caution
Scope
Supplement × Prescription
Last verified
June 4, 2026
ConflictStrong evidence
What is happening. St. John's Wort is a potent inducer of intestinal and hepatic CYP3A4, the primary enzyme that metabolizes felodipine, which already has very low oral bioavailability (about 15 percent) because of extensive first-pass metabolism. Concomitant use markedly lowers felodipine plasma concentrations and can result in loss of antihypertensive control.
Mechanism. Hyperforin in St. John's Wort activates the pregnane X receptor, upregulating CYP3A4 (and P-glycoprotein), which accelerates presystemic and hepatic metabolism of felodipine and reduces its systemic exposure.
Recommendation. Avoid combining St. John's Wort with felodipine. If a patient is already taking St. John's Wort, do not start it during felodipine therapy, and if it must be stopped, monitor blood pressure closely for several weeks because enzyme induction reverses slowly. Discuss alternatives with the prescriber.
CautionModerate evidence
What is happening. St. John's Wort can induce drug-metabolizing enzymes and transporters and may lower Felodipine exposure or undermine therapy.
Mechanism. Hyperforin induces CYP3A4 and P-glycoprotein, which can reduce exposure to susceptible drugs.
Recommendation. Avoid starting or stopping St. John's Wort without prescriber review while taking Felodipine.
Stack Score
How it moves the number.
Effect on the composite score
If both Felodipine and St. John's Wort are in the same stack, this pair applies −10 to your Stack Score (per scored conflict row).
The full algorithm, the clamping rules, and four worked stacks are at /methodology/stack-score.
SourcesSources, by evidence tier.
Every claim on this page is cited. PMIDs link straight to PubMed.
Reference material
3- 1Izzo AA, Ernst E. Interactions between herbal medicines and prescribed drugs: an updated systematic review. Drugs. 2009.Needs sourceNo link
- 2Madabushi R, Frank B, Drewelow B, et al. Hyperforin in St. John's wort drug interactions. Eur J Clin Pharmacol. 2006.Needs sourceNo link
- 3Mannel M. Drug interactions with St John's wort: mechanisms and clinical implications. Drug Saf. 2004.Needs sourceNo link